Cibus (CBUS) Other Non-Current Liabilities (2016 - 2026)
Cibus (CBUS) posted Other Non-Current Liabilities of $1.6 million for Q4 2025, up 1.56% sequentially from $1.5 million in Q3 2025, and down 99.22% YoY from $199.4 million in Q4 2024.
Cibus (CBUS) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Cibus has reported Other Non-Current Liabilities for 10 years, with the latest figure at $1.6 million in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 99.22% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (down 99.22% YoY) and the FY2025 annual result came in at $1.6 million, down 99.22% from the prior year.
- Other Non-Current Liabilities climbed to $1.6 million in Q4 2025 per CBUS's latest filing, from $1.5 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $199.4 million in Q4 2024 and troughed at $61000.0 in Q1 2023.
- A 5-year average of $64.6 million and a median of $1.5 million in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities soared 284459.02% in 2024, then tumbled 99.22% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $702000.0 in 2021, then sank by 88.6% to $80000.0 in 2022, then jumped by 206465.0% to $165.3 million in 2023, then climbed by 20.69% to $199.4 million in 2024, then sank by 99.22% to $1.6 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.6 million, $1.5 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.52 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 199.44 Mn |
| Sep 30, 2024 | 191.21 Mn |
| Jun 30, 2024 | 182.33 Mn |
| Mar 31, 2024 | 173.58 Mn |
| Dec 31, 2023 | 165.25 Mn |
| Sep 30, 2023 | 157.11 Mn |
| Jun 30, 2023 | 148.98 Mn |
| Mar 31, 2023 | 61,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Jun 30, 2022 | 68,000.00 |
| Mar 31, 2022 | 73,000.00 |
| Dec 31, 2021 | 702,000.00 |
| Sep 30, 2021 | 971,000.00 |
| Jun 30, 2021 | 1.04 Mn |
| Mar 31, 2021 | 1.21 Mn |